Mesa Laboratories (MLAB) counsel’s stock units start vesting at 34% on November 10, 2027.
Mesa Laboratories' General Counsel, Sanket Shah, reported a direct holding of 2,306 restricted stock units (RSUs) on November 10, 2026. These RSUs represent a contingent right to receive one share of common stock each. The vesting schedule for these units is 34% on November 10, 2027, 33% on November 10, 2028, and the remaining 33% on November 10, 2029.
Mesa Laboratories (MLAB) counsel Sanket Shah's 2,306 stock units vest from 2027 to 2029.
Mesa Laboratories Inc. (MLAB) General Counsel Sanket Shah directly holds 2,306 restricted stock units (RSUs), with each unit representing a contingent right to receive one common share. These RSUs will vest in three installments: 34% on November 10, 2027, 33% on November 10, 2028, and the remaining 33% on November 10, 2029. This information was reported in a Form 3 SEC filing on November 12, 2026.
Mesa Labs revenues up 2.6% to USD 62,336 in Q2 2027
Mesa Laboratories, Inc. reported a 2.6% increase in revenues to $62,336 in its second fiscal quarter ended September 30, 2026, driven by growth in Sterilization and Disinfection Control (SDC) and Calibration Solutions (CS) divisions. The company issued full-year guidance for the first time, expecting revenues between $250,000 and $255,000 and adjusted EBITDA of $66,000 to $68,000. Mesa also announced a savings plan to reduce operating costs and a new share repurchase program while focusing on profitable growth and a strong balance sheet.
Mesa Laboratories Projects $250 Million to $255 Million in Fiscal 2027 Revenue
Mesa Laboratories projects fiscal 2027 revenue between $250 million and $255 million, indicating minimal sales growth but a faster rise in adjusted EBITDA to $66 million to $68 million. The company's outlook incorporates a cost reduction plan expected to yield $5 million in net annual savings and excludes restructuring charges. Additionally, Mesa's board has authorized up to $40 million in share repurchases, funded by cash on hand and operations.
Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance
Mesa Laboratories, Inc. announced its second fiscal quarter 2027 results, reporting a 2.6% revenue increase to $62,336 and a 21.1% rise in non-GAAP Adjusted EBITDA to $17,317. The company also issued its first full-year fiscal 2027 guidance, projecting revenues of $250,000 to $255,000 and adjusted EBITDA of $66,000 to $68,000, reflecting a conservative outlook and ongoing savings initiatives. Additionally, Mesa Labs authorized a new share repurchase program of up to $40,000 and appointed Sanket Shah as Corporate Vice President, General Counsel and Secretary.
Earnings call transcript: Mesa Labs misses Q2 2026 EPS estimate, shares slip
Mesa Labs reported mixed fiscal second-quarter 2027 results, with revenue exceeding expectations but adjusted EPS falling significantly short. Despite the earnings miss and a subsequent dip in after-hours trading, the company highlighted strong year-over-year profit growth, expanded gross margins, and a positive full-year fiscal 2027 revenue guidance of $250 million to $255 million, driven by operational improvements and strategic restructuring of its Clinical Genomics business.
Mesa Laboratories Q2 2027 Earnings Call Transcript
Mesa Laboratories (NASDAQ: MLAB) reported second-quarter financial results with organic revenue growth of 2.6% and expects adjusted EBITDA to grow faster than revenues for the full fiscal year. The company announced a $9.3 million savings plan, reallocating funds to profitable growth areas and resulting in a net cost reduction of $5 million, alongside a $40 million share repurchase program. Full-year guidance projects revenues of $250 million to $255 million and adjusted EBITDA of $66 million to $68 million.
Form 8K Mesa Laboratories Inc For: 9 November By Investing.com
Mesa Laboratories Inc. (MLAB) filed a Form 8K on November 9, 2026, as reported by Investing.com. The article simply states the filing and provides the company's stock symbol and a slight price increase for the day. No further details about the content of the 8K filing are included.
Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance
Mesa Laboratories, Inc. (NASDAQ:MLAB) reported its second fiscal quarter 2027 results, with revenues increasing 2.6% to $62,336 thousand and net income up 75.3% to $4,341 thousand. The company also issued its first full-year fiscal 2027 guidance, projecting revenues of $250,000 to $255,000 thousand and adjusted EBITDA of $66,000 to $68,000 thousand. Additionally, Mesa Labs announced a new share repurchase program of up to $40,000 thousand and the appointment of Sanket Shah as Corporate Vice President, General Counsel and Secretary.
MLAB Q2 FY2027 earnings call
Mesa Laboratories reported strong second-quarter fiscal 2027 results, with revenue up 2.6% to $62.3 million and adjusted EBITDA surging 21.1% to $17.3 million. Growth was primarily driven by Sterilization and Disinfection Control (SDC) and Calibration Solutions, while Biopharmaceutical Development (BPD) and Clinical Genomics saw declines. The company also announced a restructuring plan to reduce annualized operating costs by $9.3 million and provided full-year fiscal 2027 guidance, expecting revenue of $250 million-$255 million and adjusted EBITDA of $66 million-$68 million.
How Mesa Laboratories Inc. (MLAB) Affects Rotational Strategy Timing
Mesa Laboratories Inc. (MLAB) shows strong near-term sentiment possibly leading to mid-term neutrality and a long-term positive bias, according to AI models. The analysis identifies a significant 37.9:1 risk-reward short setup and provides three distinct trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, each with specific entry, target, and stop-loss parameters.
Form 4 Mesa Laboratories Inc: John James Sullivan (Director) For: 13 October
John James Sullivan, a Director at Mesa Laboratories Inc., filed a Form 4 for transactions related to October 13. The article is a brief notification of this insider trading activity.
After a 1,200-share gift, Mesa Laboratories (MLAB) director Sullivan holds 19,418 shares directly.
Mesa Laboratories director John James Sullivan made a bona fide gift transfer of 1,200 common shares on October 13, 2026, with a reported price of $0.0000 per share. Following this transaction, Sullivan directly holds 19,418 shares. Additionally, the Sullivan Family Trust holds 45,110 shares, for which Sullivan disclaims beneficial ownership except to the extent of his pecuniary interest.
Mesa Labs Announces Second Quarter Financial Results Release Date and Earnings Conference Call
Mesa Laboratories, Inc. (NASDAQ:MLAB) will release its financial results for the second quarter of fiscal year 2027 on Thursday, November 5, 2026, after the market closes. The company will also host an earnings conference call the following morning, Friday, November 6, 2026, at 11:00 AM ET, to discuss these results. Interested parties can access the call via webcast or phone.
Mesa Labs Announces Second Quarter Financial Results Release Date and Earnings Conference Call
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced it will release its second fiscal quarter (2Q27) financial results, which ended September 30, 2026, after market close on Monday, November 9, 2026. The company will host an earnings conference call on the same day at 4:30 p.m. Eastern Time to discuss the results and conduct a Q&A session with analysts. Details for accessing the call via toll-free number, international number, or webcast have been provided.
Mesa Labs Announces Second Quarter Financial Results Release Date and Earnings Conference Call
Mesa Laboratories, Inc. announced it will release its second fiscal quarter financial results for the period ended September 30, 2026, after market close on Monday, November 9, 2026. The company will also host an earnings conference call the same day at 4:30 p.m. Eastern Time to discuss the results and conduct a Q&A session with analysts. Details for accessing the conference call via phone or webcast are provided, with a replay available for 45 days.
Mesa Labs Announces Second Quarter Financial Results Release Date and Earnings Conference Call
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced it will release its second fiscal quarter (2Q27) financial results, which ended September 30, 2026, after market close on Monday, November 9, 2026. The company will also host an earnings conference call on the same day at 4:30 p.m. Eastern Time to discuss the results and hold a Q&A session with analysts. Details for accessing the call via telephone or webcast are provided, with a replay available for 45 days on the Mesa Labs website.
Mesa Labs Announces Second Quarter Financial Results Release Date and Earnings Conference Call
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced that it will release its financial results for the second fiscal quarter (2Q27) ended September 30, 2026, after market close on Monday, November 9, 2026. The company will also host an earnings conference call on the same day at 4:30 p.m. Eastern Time to discuss the results, followed by a Q&A session with analysts. Details for accessing the conference call via phone or webcast have been provided.
BlackRock reports a passive stake in Mesa Laboratories (MLAB) and voting power over 436,324 shares.
BlackRock, Inc. has reported a beneficial ownership of 443,662 common shares, or 7.9%, in Mesa Laboratories (MLAB) as of September 30, 2026, according to a SCHEDULE 13G/A SEC filing. The investment firm holds sole voting power over 436,324 shares and sole dispositive power over 443,662 shares. This passive stake indicates that BlackRock's acquisition and holding of these securities are in the ordinary course of business and not for the purpose of changing or influencing the control of Mesa Laboratories.
Mesa Laboratories, Inc. Estimates – NASDAQ:MLAB
This article provides an overview of Mesa Laboratories, Inc. (NASDAQ: MLAB) financial data and analyst estimates available on TradingView. Users can explore reported financial data and compare actual results with average, high, and low estimates across various financial statements and valuation metrics. The platform emphasizes that this information is not investment advice and encourages users to conduct their own research.
Mesa Laboratories keeps USD 0.16 dividend for Mesa Laboratories stock
Mesa Laboratories (MLAB) has maintained its quarterly dividend at USD 0.16 per share, payable on December 15, 2026. The company reported first-quarter fiscal 2027 revenue of USD 60.14 million and earnings per share of USD 2.68. Mesa Laboratories is expected to announce its second-quarter fiscal 2027 results on November 5, 2026.
Mesa Laboratories stock fell 4.12 percent to USD 122.48 on October 16, 2026
Mesa Laboratories (MLAB) stock dropped 4.12 percent to USD 122.48 on October 16, 2026, closing below its previous Nasdaq close. The company's first-quarter fiscal 2027 revenue was USD 60.14 million, a 1.00 percent year-over-year increase, with earnings per share at USD 2.68. Investors are now looking to the second-quarter fiscal 2027 results, scheduled for November 5, 2026, after market close, and a conference call on November 9, 2026.
Mesa Laboratories stock fell 4.12 percent to USD 122.48 on October 16, 2026
Mesa Laboratories (MLAB) stock dropped 4.12% to $122.48 on October 16, 2026, closing below its previous Nasdaq price. The company reported first-quarter fiscal 2027 revenue of $60.14 million, a 1.00% year-over-year increase, with earnings per share at $2.68. Investors are anticipating the release of second-quarter fiscal 2027 results on November 5, 2026, after market close.
Mesa Laboratories stock has results scheduled for November 9, 2026
Mesa Laboratories (MLAB) is set to report its second-quarter fiscal year 2027 results and provide fiscal year 2027 guidance on November 9, 2026. The company's first-quarter revenue grew modestly by 1.00% year-over-year to $60.14 million, and its stock was trading at EUR 114.00 on October 15, 2026, with a market capitalization of $716.4 million. The upcoming guidance will reflect anticipated savings and a decrease in Clinical Genomics revenue.
Mesa Laboratories Announces Restructuring and Savings Plan
Mesa Laboratories, Inc. announced a savings plan including a global restructuring program to reduce annualized operating costs by approximately $9.3 million, with a net reduction of $5.0 million after reinvestment. The plan involves eliminating about 40 positions, primarily in the Clinical Genomics division, to focus on profitability over scale. Mesa will reinvest $4.3 million in areas like Calibration Solutions, Asia expansion, and key corporate positions to drive more profitable growth.
Mesa Laboratories Announces Restructuring and Savings Plan
Mesa Laboratories has announced a restructuring and savings plan aimed at reducing annualized operating costs by approximately $9.3 million, with a net reduction of $5.0 million after reinvestment. The plan includes eliminating about 6% of its workforce, primarily in the Clinical Genomics division, and reallocating resources to more profitable growth areas like Sterilization and Disinfection Control, Calibration Solutions, and Asia. These changes are expected to enhance profitability and focus the Clinical Genomics division on pharmacogenomics and oncology.
Mesa Laboratories to Lay Off 40 Positions; Targets $9.3 Million Annual Cost Reduction
Mesa Laboratories (MLAB) plans to eliminate 40 positions, representing 6% of its workforce, as part of a restructuring effort. This move is intended to achieve an annual cost reduction of $9.3 million. The full details of this premium article are available to subscribers.
Mesa Labs declares $0.16 quarterly dividend
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced a quarterly dividend of $0.16 per share of common stock. The dividend is scheduled to be paid on December 15, 2026, to shareholders of record as of November 30, 2026. Mesa Labs specializes in providing quality control solutions and life science tools for various industries including pharmaceutical, healthcare, and medical device sectors.
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend is payable on December 15, 2026, to shareholders of record as of November 30, 2026. Mesa Labs is a global leader in quality control solutions and life science tools for regulated industries.
Mesa Labs declares $0.16 quarterly dividend By Investing.com
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced a quarterly dividend of $0.16 per share of common stock. The dividend is scheduled for payment on December 15, 2026, to shareholders of record as of November 30, 2026. Mesa Labs specializes in quality control solutions and life science tools for the pharmaceutical, healthcare, and medical device sectors.
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 15, 2026, to shareholders of record at the close of business on November 30, 2026. Mesa Labs is a global leader in quality control solutions and life science tools for regulated applications.
A passive investor reports more than 5% ownership in Mesa Laboratories (MLAB).
Wasatch Advisors has disclosed a passive investment in Mesa Laboratories Inc. (MLAB), reporting beneficial ownership of 387,129 common shares, which constitutes 6.9% of the class. The firm holds sole voting power over 261,101 shares and sole dispositive power over all 387,129 shares. This information was detailed in a SCHEDULE 13G filing signed by CEO Mike Yeates, indicating a significant stake in the company.
Mesa Laboratories Keeps Quarterly Dividend at $0.16 per Share, Payable Dec. 15 to Holders of Record Nov. 30
Mesa Laboratories announced it will maintain its quarterly dividend at $0.16 per share. The dividend is scheduled to be paid on December 15, 2026, to shareholders who are on record as of November 30, 2026. This news was published on October 9, 2026, at 04:05 pm EDT.
Mesa Labs declares $0.16 quarterly dividend By Investing.com
Mesa Laboratories, Inc. (NASDAQ:MLAB) has announced a quarterly dividend of $0.16 per share of common stock. This dividend is scheduled to be paid on December 15, 2026, to shareholders of record as of November 30, 2026. The company specializes in designing and manufacturing quality control solutions and life science tools for various industries.
Mesa Labs declares $0.16 quarterly dividend
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced a quarterly dividend of $0.16 per share of common stock. This dividend will be paid on December 15, 2026, to shareholders of record as of November 30, 2026. The company specializes in designing and manufacturing quality control solutions and life science tools for the pharmaceutical, healthcare, and medical device industries.
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend is payable on December 15, 2026, to shareholders of record as of November 30, 2026. Mesa Labs is a global leader in quality control solutions and life science tools for regulated industries.
Mesa Laboratories Inc. Advanced Charts | MLAB
This article provides advanced chart information and financial data for Mesa Laboratories Inc. (MLAB). It includes analyst ratings, key financial metrics like P/E ratio and dividend yield, and details about the company's business segments. The page also features a peer comparison and data provider information.
Mesa Laboratories stock reports 1.00 percent Q1 revenue growth
Mesa Laboratories reported a 1.00 percent year-over-year revenue growth for Q1 fiscal 2027, reaching USD 60.14 million. Despite this revenue increase, diluted EPS declined by 42.35 percent to USD 0.49. Analysts maintain an "Equal Weight" rating with a target price below the current Nasdaq quote, highlighting the importance of future earnings growth to support its valuation.
Former Mesa Labs (NASDAQ: MLAB) officer may sell shares from stock awards
A former officer of Mesa Laboratories Inc. (MLAB), Gary M. Owens, has filed a Form 144 notice indicating his intent to sell up to 20,358 shares of common stock, valued at approximately $2.6 million. These shares were acquired through various restricted stock vesting events between 2020 and 2026 as compensation. The filing also reports two previous sales by Owens within the past three months.
Director at Mesa Laboratories (NASDAQ: MLAB) receives new stock unit grant
Mesa Laboratories director R. Tony Tripeny was granted 1,774 time-based Restricted Stock Units (RSUs) on September 9, 2026. These RSUs will vest on September 9, 2027, increasing his equity-linked holdings in the company. The grant was not made under a Rule 10b5-1 trading plan.
MESA LABORATORIES INC /CO/ Director Tripeny R Tony Granted 1,774 Derivative Securities on September 9, 2026
MESA LABORATORIES INC /CO/ Director Tripeny R Tony was granted 1,774 derivative securities on September 9, 2026. This transaction represents 100% of Tripeny R Tony’s total derivative securities holding and is classified as an award or grant. Following this award, Tripeny R Tony holds 1,774 derivative securities in the company.
Mesa Laboratories (MLAB) gives director stock units vesting in 2027
Mesa Laboratories (MLAB) director John James Sullivan was granted 1,774 Restricted Stock Units (RSUs) on September 9, 2026. These RSUs are scheduled to vest on September 9, 2027, and each unit represents a contingent right to receive one share of common stock. This grant results in Sullivan holding 1,774 RSUs directly.
Mesa Laboratories Director Shannon Hall Granted 1,774 RSUs on September 9, 2026
Mesa Laboratories Director Shannon Hall was granted 1,774 Restricted Stock Units (RSUs) on September 9, 2026, as detailed in a Form 4 filing. These RSUs, which represent a conditional right to one share of common stock each, were granted at a price of $0 and are scheduled to vest on September 9, 2027. Following this transaction, Hall directly owns 1,774 derivative securities in the company.
Mesa Laboratories (MLAB) awards stock units vesting in 2027 to a director
Mesa Laboratories (MLAB) announced that Director Mark Christopher Capone was granted 2,423 Restricted Stock Units (RSUs) on September 9, 2026. These RSUs represent a contingent right to receive one share of common stock each and are scheduled to vest on September 9, 2027. Following this grant, Mr. Capone directly holds 2,423 RSUs, increasing his equity-based compensation stake in the company.
Director awarded 1,774 RSUs at Mesa Laboratories (MLAB)
Mesa Laboratories (MLAB) director Shannon Hall was granted 1,774 Restricted Stock Units (RSUs) on September 9, 2026. These RSUs represent a contingent right to receive one share of common stock per unit and are scheduled to vest on September 9, 2027. This transaction results in Hall directly owning 1,774 RSUs after the award.
Mesa Laboratories Announces Certified Shareholder Voting Outcomes from September 2026 Annual Meeting
Mesa Laboratories, Inc. (NASDAQ: MLAB) has released the certified results from its annual shareholder meeting held on September 8, 2026. Shareholders elected all seven nominated directors for one-year terms, ratified Baker Tilly US, LLP as the independent auditor, and approved the non-binding advisory resolution on executive compensation. The company reported a strong turnout with 4,872,692 out of 5,595,869 eligible voting shares represented.
Earnings call transcript: Mesa Laboratories posts Q1 2026 revenue miss
Mesa Laboratories reported Q1 2026 revenue of $60.1 million, missing analyst forecasts due to delivery reliability issues in its Sterilization and Disinfection Control (SDC) segment, despite overall positive organic growth. CEO Siddhartha Kadia emphasized that the SDC problem is an execution issue, not a demand problem, and the company is focused on internal fixes and strengthening the balance sheet. The company anticipates providing full-year fiscal 2027 guidance in November.
Is Mesa Laboratories Inc (MLAB) Overvalued After 4.5% Rally? GF
Mesa Laboratories Inc (MLAB) shares recently rallied 4.5%, but GuruFocus' GF Value indicates the stock is currently overvalued at $124.76, exceeding its fair value estimate of $106.27. While MLAB has a strong momentum rank and an above-average GF Score of 76/100, its growth prospects are weaker, and insider selling suggests potential reservations about its current valuation. Investors are advised to exercise caution due to the lack of a margin of safety.
Former Mesa Labs (MLAB) exec files notice for August stock sale
A former officer of Mesa Laboratories Inc (MLAB), Gary M. Owens, has filed a Rule 144 notice to sell up to 20,000 shares of common stock through Fidelity Brokerage Services LLC. The aggregate market value of these shares is approximately $2.45 million. These shares were acquired through restricted stock vesting between 2018 and 2025, and Owens previously sold 3,706 shares on June 16, 2026.
Mesa Laboratories (NASDAQ: MLAB) director now holds 6,973 shares
Mesa Laboratories director Shannon Hall acquired 2,784 shares of common stock through the vesting and settlement of Restricted Stock Units (RSUs) on August 15, 2026. This transaction increased Hall's direct common stock holding to 6,973 shares, while the derivative RSU position was reduced to zero. The Form 4 filing indicates a neutral impact and sentiment regarding this insider trading activity.